Accentia Biopharmaceuticals (ABPI) Conducts Investigator Meeting in Preparation for New Multiple Sclerosis Drug Study for Cyrevia™
5/4/2012 10:05:40 AM
TAMPA, Fla.--(BUSINESS WIRE)--Accentia Biopharmaceuticals, Inc. (OTCQB:ABPI) today announced that the Company and leading physicians from Johns Hopkins University co-hosted a meeting with prospective clinical trial investigators at the recent American Academy of Neurology (AAN) Annual Meeting in New Orleans. The Company and investigators from Johns Hopkins University presented plans for a randomized clinical trial to study Cyrevia™ (formerly Revimmune™) in multiple sclerosis (MS) to a number of key opinion leaders in the field and potential site investigators. Johns Hopkins University will serve as the lead trial site for the study.